Media about us

• Metastatic Breast Cancer Clinical Trial Forged by Epic Sciences, Canadian Consortium

  07 November 2018 GenomeWeb

  

  Epic Sciences announced today that it has partnered with four major Canadian breast cancer centers on a clinical trial to see if the firm's blood test can be used to predict the risk of late recurrence of metastatic breast cancer in female patients. The Canadian centers include Mount Sinai Hospital's Marvelle Koffler Breast Centre, the Princess Margaret Cancer Centre, Sunnybrook Odette Cancer Centre, and BC Cancer.

• PharmNews: NovaMedica Innotech debuts on CPhI

  09 October 2018

  

  The international exhibition CPhI has started in Madrid. And today NovaMedica Innotech is in our focus as the company that has made a bright debut at the exhibition. This Technological Center has launched in April 2017 and Moscow Mayor Sergei Sobyanin attended the opening ceremony.

• How Can the Russian R&D Industry Help the Global One?

  03 October 2018 CIS GMP news Magazine, Autumn 2018

  

  The current model of the pharmaceutical business in the context of R&D in Russia reflects the world trends. One of the striking examples is R&D Center of NovaMedica Innotech. It belongs to the group of CDMO (contract development and manufacturing organizations), whose task is to provide services following the 'one contact’ principle: pharmaceutical development, technology development, technology transfer, and manufacturing of small batches of products - both for clinical trials and for manufacturing of finished products batches (based on the GMP license).

• The “Pharma-2030” Strategy: Promoting Globalization

  03 October 2018 CIS GMP news Magazine, Autumn 2018

  

  The pharmaceutical market has been actively discussing Pharma-2030 Strategy, which is currently being developed. The opinions and assessments that we hear are often quite different, if not diametrically opposite. The concept of the program must incorporate the interests of all market participants, including manufacturers, who must understand the general trend, the goals and objectives for further development, and the resources they have available for that work. We asked Alexander Kuzin, General Director of NovaMedica Company, to share his opinion of the program as a representative of the manufacturing sector.

• Kaluga Pharmaceutical Cluster

  03 October 2018 CIS GMP news Magazine, Autumn 2018

  

  Business gave credence to the government course of developing pharmaceutics. Interview with Vice-Governor of Kaluga Region Vladimir Popov: This year, NovaMedica Company got approval for the conclusion of special investment contract. NovaMedica Company will additionally invest more than 3 billion rubles in modernization of its plant and in technology transfer within the frame of this contract.

• Penetrating the European Market

  02 October 2018 CIS GMP news Magazine, Autumn 2018

  

  NovaMedica Innotech is a first-timer at Cphl WorldWide. This is the first opportunity for the company to introduce its products to the European market. NovaMedica Innotech Technology Centre opened its doors in April 2017 in Moscow. It possesses a unique range of innovative Technology platforms for the development and pilot productions of advanced, completive and effective pharmaceuticals.

• Researchers provide compelling evidence for multiple STI-detecting device

  11 September 2018 St. George's University of London / Medical Xpress

  

  Using mathematical modelling, researchers within the Applied Diagnostics Research and Evaluation Unit at the university concluded that a bespoke point-of care diagnostic device could significantly reduce the number of return clinical visits and the average time-to-cure from about a week to one day. The device is in early phases of development by Atlas Genetics Limited, following a grant from from Innovate UK via the Small Business Research Initiative.

• Blood Test Can Identify Patient Response to Prostate Cancer Treatments

  17 August 2018 Jennifer Barrett / Specialty Pharmacy Times

  A blood test can help detect whether patients with advanced prostate cancer will respond to a certain treatment, according to a new study. This approach could help better inform the choice of therapy and lead to improved outcomes. In the study, researchers used a liquid biopsy test developed by Epic Sciences to examine circulating tumor cells (CTCs) in blood samples from 142 patients with advanced prostate cancer deciding whether to switch from hormone-targeting therapy to chemotherapy.

• Celtaxsys’ cystic fibrosis drug reduces lung exacerbations in phase 2 study

  03 August 2018 Conor Hale / FierceBiotech

  

  Celtaxsys’ oral anti-inflammatory drug for cystic fibrosis, acebilustat, cleared a phase 2 study by demonstrating meaningful improvements in pulmonary exacerbations, or the acute worsening of symptoms such as heavy coughing or shortness of breath, combined with sharp decreases in lung function following irreversible organ damage.

• Russia registered a unique drug for the treatment of proctological disorders

  29 June 2018 GMP News

  

  NovaMedica, a Russian pharmaceutical manufacturer and portfolio company of RUSNANO, has registered Fissario®, a unique drug for the treatment of proctological disorders based on a new mechanism of action not used in the products currently available on the market. This is the first drug developed under NovaMedica’s own R&D program. According to the plans, it will become available to patients as early as in 2019.